Authorities Probe Substandard Rabies Vaccine Batch KE25012 Seized in Delhi
September 06, 2026 at 2:16 AM1 min read
AI Summary
Authorities are investigating a batch of Abhayrab rabies vaccine, bearing batch number KE25012, seized from an unlicensed residential premises in Mukherjee Nagar, Delhi. The Central Drugs Laboratory reported the samples as “not of standard quality” and misbranded after testing. Indian Immunologicals Ltd stated that these vials were not manufactured by Human Biologicals Institute, a division of the company, and requested authorities trace their source. Abhayrab is used for pre- and post-exposure protection against rabies and is supplied to government immunization programs in India.
World View
1 perspectiveIndia's perspective
The HinduEconomic Times
Indian Immunologicals Ltd has said vials of its Abhayrab rabies vaccine, bearing batch number KE25012 and seized from an unlicensed premises in Delhi, were not manufactured by Human Biologicals Institute, a division of the company, and has asked authorities to trace their source and act against those responsible. Abhayrab is a human rabies vaccine used for both pre- and post-exposure protection against rabies and is also supplied to government immunisation programmes in India.
Analysis
The sources agree on the investigation into batch KE25012, which was seized from an unlicensed premises in Delhi. The Central Drugs Laboratory reported that the samples were “not of standard quality” and misbranded. Indian Immunologicals Ltd stated that these vials were not a product of Human Biologicals Institute, asking authorities to act against those responsible.
The Hidden Strings
Patterns visible only when every country's coverage is placed side by side — the connections no single source draws.
Vocabulary
The Vocabulary String: Commerce vs. Compliance
95%
Cluster A employs highly specialized corporate and supply chain jargon ('immunologicals', 'supplied', 'market') centered on ownership disputes. Conversely, Cluster B uses technical regulatory language ('counterfeit', 'misbranded', 'failed a potency test'), indicating that the narrative focus shifts entirely from commercial sourcing to official quality control failure.
Cluster A: vocabulary (immunologicals, supplied, market)Cluster B: vocabulary (counterfeit, misbranded, failed a potency test)
Silence
The Silence of Source Tracing vs. Quality Failure
90%
While Cluster A dedicates its entire narrative to tracing the source and denying ownership ('not mine'), it completely omits any mention of the core regulatory finding: that the vaccine failed a potency test. This suggests an attempt to redirect attention away from product quality failure toward supply chain accountability.
Cluster A: vocabulary (trace their source)Cluster B: vocabulary (failed a potency test)
Timing
The Narrative Lead: Denial Precedes Investigation
85%
The timeline shows that the corporate denial and ownership dispute were reported first by The Economic Times at 13:38. The more authoritative regulatory finding regarding 'counterfeit' status was published later, at 17:24, suggesting a deliberate sequencing of narratives from source dispute to official failure confirmation.
2026-09-05T13:38 India Economic Times2026-09-05T17:24 India The Hindu
How Each Side Framed It
Corporate Denial and Source Tracing
India
Favors IIL by establishing clear boundaries of non-responsibility.
not mineunlicensed premisestrace their source
Regulatory Failure and Fraud Investigation
India
Favors the regulatory authority's findings regarding illegality.
authorities probing‘counterfeit’misbrandedfailed a potency test
What Mainstream Coverage Missed
Angles present in the cross-border material that the dominant coverage buried or skipped.
- The narrative shifts from ownership disputes to regulatory failure: The vocabulary string shows a deliberate pivot from corporate jargon ('immunologicals') to technical quality control language ('misbranded', 'potency test').
- The timing suggests a strategic sequencing of information: Corporate denial regarding source was reported hours before the official, authoritative finding of counterfeit status.
- The core regulatory failure,that the vaccine failed a potency test,is consistently omitted from the corporate defense, which focuses exclusively on tracing the product's origin.
The Beyond the Borders PoV
The Question
What regulatory steps must be taken to ensure that all rabies vaccines supplied for government immunization programs meet mandated quality standards and verifiable supply chain integrity?
The government must implement mandatory, verifiable regulatory steps to ensure all rabies vaccines meet mandated quality standards and maintain supply chain integrity.
Concerns regarding the identity and authenticity of Abhayrab batch KE25012 have prompted authorities to investigate suspected counterfeit vaccines. The Central Drugs Laboratory reported that seized samples were 'not of standard quality' and misbranded, leading the Drugs Controller General to ask state regulators to maintain 'strict vigilance' over its distribution.
The discovery of seized samples deemed 'not of standard quality' necessitates mandatory regulatory steps because substandard vaccines pose a direct public health risk that could undermine immunization programs and patient safety.
To prevent the circulation of unauthorized products, regulatory steps must mandate strict oversight over vaccine movement and distribution channels, as evidenced by the Drugs Controller General's directive to maintain 'strict vigilance'.
The investigation into suspected counterfeit vaccines and the denial of producing misbranded vials highlight the critical need for regulatory measures that verify both manufacturing origin and product authenticity to protect public trust.
These are AI-generated arguments built from the evidence available across the source material. They do not imply that any publisher endorses either position.
Disclaimer
The summary and perspectives above are AI-generated from the source articles listed below. They may contain errors or omissions. Always verify with the original sources. Beyond the Borders is a news aggregation platform and does not produce original journalism.
How does this story make you feel?
What each source is saying
2 sourcesTheir Angle
Authorities are probing the vaccine manufacturer's denial regarding 'misbranded' vials bearing batch number KE25012, which failed a potency test by the Central Drugs Laboratory.
Article Preview
The manufacturer of the vaccine has denied producing the ‘misbranded’ vials bearing batch number KE25012 which failed a potency test by the Central Drugs Laboratory
More from health
PreviousbusinessUS Sanctions Turkish Bank Over Alleged Transactions for Iranian ForcesNextbusinessMajor Chinese Banks Plan A-Share Issuances to Boost Core Tier-1 Capital
Discussion
Leave a comment